The Value of Partnering and Venture Capital to be Explored at BIO VentureForum East 2006

Search Blogs that Mention this News Release
Click this link to view linked Bookmarking Services
Click this link to view linked Blogging Services
The Value of Partnering and Venture Capital to be Explored at BIO VentureForum East 2006
    WASHINGTON, June 2 /PRNewswire/ -- The Biotechnology Industry
Organization (BIO) announced today the speakers for BIO VentureForum East
2006, scheduled June 12-14th at the Hyatt Regency on the Hudson in Jersey
City, NJ.
    BIO VentureForum East is the largest annual East Coast regional
investor conference for venture stage biotechnology and healthcare firms.
It features plenary sessions and workshops on financing and partnering
trends in the biotechnology industry, networking receptions, and
presentations by biotech companies which have been selected by an advisory
board of leading equity capital leaders.
    The plenary session from 8:30-9:45 a.m. on Tuesday, June 13th, will be
a roundtable discussion on "To Partner or Not: Weighing the Value of the
Deal." Financial and biotech executives will discuss various business
strategies and funding alternatives. Kevin Collins, shareholder,
Corporate/VLG Practice Group, Heller Ehrman LLP, will moderate the
discussion with:
    * Jason Bernhard, Global Co-Head, Life Sciences Group, Lazard;

    * Dan Greenleaf, President & CEO, VioQuest Pharmaceuticals, Inc.;

    * Tucker Kelly, Principal, Life Sciences Investment Banking, Canaccord
      Adams;

    * Zubin Mory, Senior Vice President, Investment Banking, Oppenheimer &
      Co., Inc.;

    * Michael Weiser, M.D., Ph.D., Managing Director, Paramount BioCapital,
      Inc.
    "What Excites VCs Today?" is the topic of the plenary session on
Wednesday, June 14th, from 8:30-9:45 a.m. This panel will discuss the value
of specific business models, partnering agreements, technologies and exit
strategies in attracting healthcare venture capital investment. Todd Brady,
M.D., Ph.D., Principal, Domain Associates, LLC, will moderate the
discussion with:
    * Roger Blevins, Pharm.D., President and CEO, Xsira Pharmaceuticals, Inc.;

    * Aaron Davidson, M.B.A., Managing Director, H.I.G. Ventures;

    * Chris Kroeger, M.D., Principal, Aurora Funds;

    * Matthew Rieke, M.D., Partner, Quaker BioVentures.
    Mervyn Turner, Ph.D., Senior Vice President of Worldwide Licensing &
External Research for Merck Research Laboratories, will deliver Tuesday's
keynote luncheon address entitled "Opportunities for Early Stage Companies
to Partner with Big Pharma."
    On Wednesday, Michael J. Valentino, President and CEO of Adams
Respiratory Therapeutics, Inc., will deliver the luncheon keynote entitled
"The Transformation From VC-backed Firm to Public Entity."
    For more information about BIO VentureForum East, please visit
http://bvf-east.bio.org/opencms/bvfeast/2006/index.jsp.
    Registration is complimentary for credentialed members of the news
media. Advance media registration is available online through 5pm EDT on
June 5th at
http://bvf-east.bio.org/opencms/bvfeast/2006/registration/mediareg.html.
Reporters and editors working full-time for print or broadcast news
organizations may also register onsite with valid media credentials.
    BIO represents more than 1,100 biotechnology companies, academic
institutions, state biotechnology centers and related organizations across
the United States and 31 other nations. BIO members are involved in the
research and development of healthcare, agricultural, industrial and
environmental biotechnology products.
SOURCE Biotechnology Industry Organization
http://www.bio.org/
CONTACT:
Stephanie Fischer of Biotechnology Industry
Organization, +1-202-312-9263